The SELECT cardiovascular outcomes trial established that semaglutide reduces major adverse cardiovascular events by 20%, providing a strong clinical rationale for treatment that extends beyond weight management alone
Jeremy Brown, a research collaborator with CAUSALab, was the corresponding author
While these drugs offer impressive results for weight loss and blood sugar control, growing evidence suggests they may come with concerning long-term effects that arent always discussed in the consultation room
PREMIUM INGREDIENTS: Powered by the most premium all-natural sources of fiber, our patented blend of unripened green bananas, oat beta glucan, and resistant potato starch is clinically-proven to support digestion and metabolic health
Meanwhile, semaglutide (Ozempic) is now FDAapproved for reducing the risk of kidney disease progression and renal outcomes in people with type 2 diabetes and chronic kidney disease
Weight loss that depends on feeling sick, skipping meals, or being unable to eat enough protein is not the same as medically supervised fat loss with muscle preservation
